Prelude Therapeutics’ IPO


Fenwick & West LLP advised Prelude Therapeutics Inc. on the deal.

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced the closing of its initial public offering of 9,573,750 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1,248,750 additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to Prelude Therapeutics from the offering were approximately $181.9 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Prelude Therapeutics.

Prelude Therapeutics’ common stock began trading on the Nasdaq Global Select Market on September 25, 2020 under the ticker symbol “PRLD”.

Morgan Stanley, Goldman Sachs & Co. LLC and BofA Securities acted as joint book-running managers for the offering.

The Fenwick transaction team included corporate partners Robert Freedman (Picture) and Effie Toshav and associates Julia Forbess, Alice Lin, Andrew Murphy, Emily Yi, Mitchell Duncombe and John Clancy; as well as executive compensation and employee benefits partner Mathew Cantor.

Involved fees earner: Matthew Cantor – Fenwick & West LLP; John Clancy – Fenwick & West LLP; Mitchell Duncombe – Fenwick & West LLP; Julia Forbess – Fenwick & West LLP; Robert Freedman – Fenwick & West LLP; Alice Lin – Fenwick & West LLP; Andrew Murphy – Fenwick & West LLP; Effie Toshav – Fenwick & West LLP; Emily Yi – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Prelude Therapeutics;

Author: Ambrogio Visconti